HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental data Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peres, M. F. P. Articles by Young, W. B. Search for Related Content PubMed PubMed Citation Articles by Peres, M. F. P. Articles by Young, W. B. Related Collections All Headache Migraine

Hemicrania continua is not that rare

From the Jefferson Headache Center (Drs. Peres and Silberstein and A.L. Shechter) and the Department of Neurology (Drs. Rozen and Young and S. Nahmias), Thomas Jefferson University Hospital, Philadelphia, PA; and the Department of Neurology (Dr. Youssef), Temple University Hospital, Philadelphia, PA.

Address correspondence and reprint requests to Dr. Mario F.P. Peres, Jefferson Headache Center, Neurology, Thomas Jefferson University Hospital, 111 South Eleventh Street, Gibbon Building, Suite #8130, Philadelphia, PA 19107; e-mail: marioperes{at}yahoo.com

Background:— Hemicrania continua is an indomethacin-responsive headache disorder characterized by a continuous, moderate to severe, unilateral headache. More than 90 cases of hemicrania continua have been reported, but there is still uncertainty about its clinical features.

Methods:— The authors compared 34 new cases (24 women, 10 men) with previously reported cases. All the patients met Goadsby and Lipton’s proposed criteria. The authors compared baseline (continuous background headache) and exacerbation (attacks of severe periods of headaches).

Results:— The baseline headache was typically mild to moderate in intensity and usually not associated with severe disability. In contrast, the headache exacerbations were severe and associated with photophobia, phonophobia, nausea, and disability. At least one autonomic symptom was present in 25 patients (74%). Jabs and jolts were present in 14 patients (41%). The mean indomethacin dose was 136.7 ± 60 mg (range 25 to 225 mg). Twenty-four patients (70.6%) met International Headache Society criteria for migraine in their exacerbation period. Occipital tenderness was observed in 23 patients (67.6%). The temporal pattern was remitting in four patients (11.8%), continuous from onset in 18 (52.9%), and continuous evolving from remitting in 12 (35.3%).

Conclusion:— Hemicrania continua is not a rare disorder. All cases of chronic unilateral daily headaches should receive an indomethacin trial early if not first in treatment.

This article has been cited by other articles:

				S. D. Silberstein Chronic Daily Headache J Am Osteopath Assoc, April 1, 2005; 105(4_suppl): 23S - 29S. [Abstract] [Full Text] [PDF]

				R.B. Lipton, S.D. Silberstein, J.R. Saper, M.E. Bigal, and P.J. Goadsby Why headache treatment fails Neurology, April 8, 2003; 60(7): 1064 - 1070. [Abstract] [Full Text] [PDF]

				E. L. H. Spierings, O. Sjaastad, M. F. P. Peres, S. D. Silberstein, W. B. Young, and T. D. Rozen Hemicrania continua is not that rare Neurology, August 13, 2002; 59(3): 476 - 477. [Full Text] [PDF]

				Developing Diagnostic Criteria for Hemicrania Continua Journal Watch Neurology, April 26, 2002; 2002(426): 3 - 3. [Full Text]

Correspondence: